Can HER2 Targeted PET/CT Imaging Identify Unsuspected HER2 Positive Breast Cancer Metastases, Which Are Amenable to HER2 Targeted Therapy?

Completed · Not applicable

Conditions studied: Breast Cancer Metastases, HER2 Positive Breast

In brief

Some breast cancer cells make a protein called Human Epidermal Growth factor receptor 2 (HER2). Patients with HER2 positive (HER2+) breast cancer receive medicine that attacks HER2, which helps these patients live longer. Some HER2 negative (HER2-) breast cancer patients also benefit from medicines that attack HER2, but we do not know why or which patients will benefit. This study uses a new imaging method, HER2-targeted PET/CT, to identify patients that may benefit from medicines that attack HER2. This is experimental.

Key facts

Study ID

NCT02286843

Run by

Memorial Sloan Kettering Cancer Center

People needed

49

Starts

2014-11-06

Expected to finish

2020-06-30

Last updated by the study team

2021-06-18

Who can join

Age: 18 and older. Sex: female. Healthy volunteers: not accepted.

You may qualify if…

• Women age > 18
• Biopsy proven HER2 negative primary breast cancer and biopsy proven metastatic disease.
• 5 or more foci of demonstrable metastases on recent imaging modalities (CT, MR, FDG PET/CT)
• ECOG performance score of 0-2

You may not qualify if…

• Life expectancy < 3months
• Pregnancy or lactation
• Patients who cannot undergo PET/CT scanning because of weight limits
• CNS only disease on recent imaging

Where it is running

• Memorial Sloan Kettering Cancer Center — New York, New York, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.